Envestnet Portfolio Solutions Inc. Purchases 13,311 Shares of AstraZeneca PLC (NASDAQ:AZN)

Envestnet Portfolio Solutions Inc. grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 13.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 115,428 shares of the company's stock after acquiring an additional 13,311 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in AstraZeneca were worth $7,774,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Anchor Investment Management LLC acquired a new stake in shares of AstraZeneca in the fourth quarter valued at $26,000. Compagnie Lombard Odier SCmA acquired a new stake in shares of AstraZeneca in the fourth quarter valued at $27,000. Nemes Rush Group LLC lifted its holdings in shares of AstraZeneca by 375.6% in the third quarter. Nemes Rush Group LLC now owns 428 shares of the company's stock valued at $29,000 after buying an additional 338 shares during the period. Northwest Financial Advisors acquired a new stake in shares of AstraZeneca in the fourth quarter valued at $34,000. Finally, LWM Advisory Services LLC acquired a new stake in shares of AstraZeneca during the third quarter worth $35,000. Institutional investors and hedge funds own 20.35% of the company's stock.

AstraZeneca Stock Performance

Shares of AZN stock traded up $0.25 during trading hours on Monday, reaching $77.43. 2,565,597 shares of the company's stock were exchanged, compared to its average volume of 6,248,794. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $77.93. The company has a quick ratio of 0.70, a current ratio of 0.89 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of $240.07 billion, a P/E ratio of 37.90, a P/E/G ratio of 1.40 and a beta of 0.47. The business has a fifty day moving average price of $69.53 and a 200-day moving average price of $66.79.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.74 by ($0.01). AstraZeneca had a return on equity of 30.42% and a net margin of 13.30%. The company had revenue of $12.02 billion for the quarter, compared to the consensus estimate of $12.07 billion. During the same quarter in the previous year, the firm posted $0.69 EPS. The business's revenue for the quarter was up 7.3% compared to the same quarter last year. Analysts predict that AstraZeneca PLC will post 4.03 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Morgan Stanley assumed coverage on AstraZeneca in a research report on Tuesday, January 23rd. They set an "overweight" rating on the stock. BMO Capital Markets upped their price target on AstraZeneca from $80.00 to $82.00 and gave the company an "outperform" rating in a research report on Friday, April 26th. Finally, Deutsche Bank Aktiengesellschaft raised AstraZeneca from a "sell" rating to a "hold" rating in a research report on Tuesday, April 16th. Three analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $81.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.